Tranexamic acid is an active site inhibitor of urokinase plasminogen activator

  • Blood Adv. 2019 Mar 12;3(5):729-733. doi: 10.1182/bloodadvances.2018025429.
Guojie Wu  1  2 ,  Blake A Mazzitelli  1  2 ,  Adam J Quek  1  2 ,  Matthew J Veldman  1  2 ,  Paul J Conroy  1  2 ,  Tom T Caradoc-Davies  1  2  3 ,  Lisa M Ooms  1  2 ,  Kellie L Tuck  4 ,  Jonathan G Schoenecker  5 ,  James C Whisstock  1  2  6 ,  Ruby H P Law  1  2
Affiliations
  • 1. ARC Centre of Excellence in Advanced Molecular Imaging, and.
  • 2. Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia.
  • 3. Australian Synchrotron, Clayton, Australia.
  • 4. School of Chemistry, Monash University, Melbourne, Australia.
  • 5. Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN; and.
  • 6. South East University-Monash Joint Institute, Institute of Life Sciences, Southeast University, Nanjing, China.
PMID: 30814058 DOI: 10.1182/bloodadvances.2018025429
Abstract

  1. TXA is an active-site inhibitor of uPA.

  2. TXA attenuates MDA-MB-231 BAG cell migration and inhibits endogenous uPA activity.

Products